Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDAData presented at the...
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells...
Nuvectis Pharma to Present at the 36th Annual Roth Conference
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800
Nuvectis Reports Fiscal Year 2023 Financial Results and Business Highlights
Mitesh Borad, M.D., will serve as the Principal Investigator for the clinical trialThe Investigator-sponsored clinical trial follows the robust preclinical proof of concept data generated by...